294 related articles for article (PubMed ID: 28027586)
1. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
McCommis KS; Hodges WT; Brunt EM; Nalbantoglu I; McDonald WG; Holley C; Fujiwara H; Schaffer JE; Colca JR; Finck BN
Hepatology; 2017 May; 65(5):1543-1556. PubMed ID: 28027586
[TBL] [Abstract][Full Text] [Related]
2. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
[TBL] [Abstract][Full Text] [Related]
3. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.
Ferguson D; Eichler SJ; Yiew NKH; Colca JR; Cho K; Patti GJ; Shew TM; Lutkewitte AJ; Mukherjee S; McCommis KS; Niemi NM; Finck BN
Mol Metab; 2023 Apr; 70():101694. PubMed ID: 36801448
[TBL] [Abstract][Full Text] [Related]
5. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
Colca JR; McDonald WG; Adams WJ
Expert Opin Investig Drugs; 2018 Jul; 27(7):631-636. PubMed ID: 29950116
[TBL] [Abstract][Full Text] [Related]
6. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
Kamm DR; Pyles KD; Sharpe MC; Healy LN; Colca JR; McCommis KS
J Biol Chem; 2021; 296():100807. PubMed ID: 34022222
[TBL] [Abstract][Full Text] [Related]
7. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
8. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction.
Li S; Li X; Chen F; Liu M; Ning L; Yan Y; Zhang S; Huang S; Tu C
J Nutr Biochem; 2022 Feb; 100():108888. PubMed ID: 34695558
[TBL] [Abstract][Full Text] [Related]
9. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
[TBL] [Abstract][Full Text] [Related]
11. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
12. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).
Sharma RS; Harrison DJ; Kisielewski D; Cassidy DM; McNeilly AD; Gallagher JR; Walsh SV; Honda T; McCrimmon RJ; Dinkova-Kostova AT; Ashford MLJ; Dillon JF; Hayes JD
Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):367-398. PubMed ID: 29552625
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
Win S; Min RWM; Zhang J; Kanel G; Wanken B; Chen Y; Li M; Wang Y; Suzuki A; Aung FWM; Murray SF; Aghajan M; Than TA; Kaplowitz N
Hepatology; 2021 Dec; 74(6):3127-3145. PubMed ID: 34331779
[TBL] [Abstract][Full Text] [Related]
14. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
15. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
16. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-Mediated RNA Therapy Attenuates Nonalcoholic Steatohepatitis and Related Fibrosis by Targeting Activated Hepatic Stellate Cells.
Zhang C; Teng Y; Li F; Ho W; Bai X; Xu X; Zhang XQ
ACS Nano; 2023 Aug; 17(15):14852-14870. PubMed ID: 37490628
[TBL] [Abstract][Full Text] [Related]
18. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway.
Ni XX; Li XY; Wang Q; Hua J
J Physiol Biochem; 2021 Feb; 77(1):35-45. PubMed ID: 33188625
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
Gupte AA; Liu JZ; Ren Y; Minze LJ; Wiles JR; Collins AR; Lyon CJ; Pratico D; Finegold MJ; Wong ST; Webb P; Baxter JD; Moore DD; Hsueh WA
Hepatology; 2010 Dec; 52(6):2001-11. PubMed ID: 20938947
[TBL] [Abstract][Full Text] [Related]
20. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.
Zhou J; Tripathi M; Ho JP; Widjaja AA; Shekeran SG; Camat MD; James A; Wu Y; Ching J; Kovalik JP; Lim KH; Cook SA; Bay BH; Singh BK; Yen PM
Thyroid; 2022 Jun; 32(6):725-738. PubMed ID: 35317606
[No Abstract] [Full Text] [Related]
[Next] [New Search]
